https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Adv. Immunol. 2006;90:243-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Adv. Immunol. 2006;90:243-952006-01-01 00:00:002019-02-15 09:19:49Immunity to melanoma antigens: from self-tolerance to immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-42006-01-01 00:00:002019-02-15 09:19:53Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-172006-01-01 00:00:002019-02-15 09:24:18Immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-152005-12-15 00:00:002019-02-15 09:25:39Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-722005-12-15 00:00:002019-02-15 09:25:40Natural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-182005-12-06 00:00:002019-02-15 09:19:47Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-682005-12-01 00:00:002019-02-15 08:49:34Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Pathology 2005 Dec;37(6):534-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Pathology 2005 Dec;37(6):534-502005-12-01 00:00:002019-02-15 08:51:27Vaccine strategies to treat lymphoproliferative disorders
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Ann. N. Y. Acad. Sci. 2005 Dec;1062:13-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Ann. N. Y. Acad. Sci. 2005 Dec;1062:13-212005-12-01 00:00:002019-02-15 09:00:03Harnessing the immune system against human glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Int J Hyperthermia 2005 Dec;21(8):723-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Int J Hyperthermia 2005 Dec;21(8):723-92005-12-01 00:00:002019-02-15 09:17:45Thermal regulation of lymphocyte trafficking: hot spots of the immune response
